Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study)
Identifieur interne : 004278 ( Main/Merge ); précédent : 004277; suivant : 004279Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study)
Auteurs : Wolfgang H. Oertel [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Bettina Bergtholdt [Allemagne] ; Yngve Hallström [Suède] ; Jaan Albo [Suède] ; Lena Leissner [Suède] ; Thomas Schindler [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne]Source :
- Movement disorders [ 0885-3185 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks. Overall, 345 patients were randomly assigned in a 1:2 ratio to receive either placebo (n = 115) or pramipexole (n = 230) with a starting dose of 0.125 mg/day. The dose was individually optimized according to the Patient Global Impression (PGI) assessment, up to a maximum of 0.75 mg/day. The primary endpoint consisted of two assessments: the change from baseline in the International RLS Study Group Rating Scale (IRLS) and the proportion of patients with Clinical Global Impressions-Improvement (CGI-I) assessments of "much/very much improved" (CGI-I responders) at week 6. Secondary endpoints included PGI and IRLS responder rates. Patient demographics and baseline characteristics were comparable between treatment groups. At baseline, mean IRLS scores were 24.9 (placebo) and 24.7 (pramipexole), representing severely affected patients. After 6 weeks, adjusted mean reductions (±SE) in IRLS score were 5.7 (±0.9) for placebo (median dose 0.47 mg/day) and 12.3 (±0.6) for pramipexole (median dose 0.35 mg/day; P < 0.0001). CGI-I responder rates were 32.5% (placebo) and 62.9% (pramipexole) (P < 0.0001). For all secondary endpoints, pramipexole showed superior results. Pramipexole was well tolerated throughout the study.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001806
- to stream PascalFrancis, to step Curation: 001515
- to stream PascalFrancis, to step Checkpoint: 001688
Links to Exploration step
Pascal:07-0133246Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study)</title>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Philipps-University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stiasny Kolster, Karin" sort="Stiasny Kolster, Karin" uniqKey="Stiasny Kolster K" first="Karin" last="Stiasny-Kolster">Karin Stiasny-Kolster</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Philipps-University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bergtholdt, Bettina" sort="Bergtholdt, Bettina" uniqKey="Bergtholdt B" first="Bettina" last="Bergtholdt">Bettina Bergtholdt</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Emovis GmbH</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hallstrom, Yngve" sort="Hallstrom, Yngve" uniqKey="Hallstrom Y" first="Yngve" last="Hallström">Yngve Hallström</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Neuro Center</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Albo, Jaan" sort="Albo, Jaan" uniqKey="Albo J" first="Jaan" last="Albo">Jaan Albo</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Läkarhuset Vallingby</s1>
<s2>Vällingby</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Läkarhuset Vallingby</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leissner, Lena" sort="Leissner, Lena" uniqKey="Leissner L" first="Lena" last="Leissner">Lena Leissner</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Neurologiska Kliniken</s1>
<s2>Örebro</s2>
<s3>SWE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Neurologiska Kliniken</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schindler, Thomas" sort="Schindler, Thomas" uniqKey="Schindler T" first="Thomas" last="Schindler">Thomas Schindler</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reess, Juergen" sort="Reess, Juergen" uniqKey="Reess J" first="Juergen" last="Reess">Juergen Reess</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0133246</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0133246 INIST</idno>
<idno type="RBID">Pascal:07-0133246</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001806</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001515</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001688</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Oertel W:efficacy:of:pramipexole</idno>
<idno type="wicri:Area/Main/Merge">004278</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study)</title>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Philipps-University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stiasny Kolster, Karin" sort="Stiasny Kolster, Karin" uniqKey="Stiasny Kolster K" first="Karin" last="Stiasny-Kolster">Karin Stiasny-Kolster</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Philipps-University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bergtholdt, Bettina" sort="Bergtholdt, Bettina" uniqKey="Bergtholdt B" first="Bettina" last="Bergtholdt">Bettina Bergtholdt</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Emovis GmbH</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hallstrom, Yngve" sort="Hallstrom, Yngve" uniqKey="Hallstrom Y" first="Yngve" last="Hallström">Yngve Hallström</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Neuro Center</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Albo, Jaan" sort="Albo, Jaan" uniqKey="Albo J" first="Jaan" last="Albo">Jaan Albo</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Läkarhuset Vallingby</s1>
<s2>Vällingby</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Läkarhuset Vallingby</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leissner, Lena" sort="Leissner, Lena" uniqKey="Leissner L" first="Lena" last="Leissner">Lena Leissner</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Neurologiska Kliniken</s1>
<s2>Örebro</s2>
<s3>SWE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>Neurologiska Kliniken</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schindler, Thomas" sort="Schindler, Thomas" uniqKey="Schindler T" first="Thomas" last="Schindler">Thomas Schindler</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reess, Juergen" sort="Reess, Juergen" uniqKey="Reess J" first="Juergen" last="Reess">Juergen Reess</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharma GmbH & Co. KG</s1>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
<wicri:noRegion>Boehringer Ingelheim Pharma GmbH & Co. KG</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Multicenter study</term>
<term>Nervous system diseases</term>
<term>Pramipexole</term>
<term>Restless legs syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Impatience membre inférieur syndrome</term>
<term>Pramipexole</term>
<term>Etude multicentrique</term>
<term>Etude double insu</term>
<term>Essai clinique</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks. Overall, 345 patients were randomly assigned in a 1:2 ratio to receive either placebo (n = 115) or pramipexole (n = 230) with a starting dose of 0.125 mg/day. The dose was individually optimized according to the Patient Global Impression (PGI) assessment, up to a maximum of 0.75 mg/day. The primary endpoint consisted of two assessments: the change from baseline in the International RLS Study Group Rating Scale (IRLS) and the proportion of patients with Clinical Global Impressions-Improvement (CGI-I) assessments of "much/very much improved" (CGI-I responders) at week 6. Secondary endpoints included PGI and IRLS responder rates. Patient demographics and baseline characteristics were comparable between treatment groups. At baseline, mean IRLS scores were 24.9 (placebo) and 24.7 (pramipexole), representing severely affected patients. After 6 weeks, adjusted mean reductions (±SE) in IRLS score were 5.7 (±0.9) for placebo (median dose 0.47 mg/day) and 12.3 (±0.6) for pramipexole (median dose 0.35 mg/day; P < 0.0001). CGI-I responder rates were 32.5% (placebo) and 62.9% (pramipexole) (P < 0.0001). For all secondary endpoints, pramipexole showed superior results. Pramipexole was well tolerated throughout the study.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Suède</li>
</country>
<region><li>Berlin</li>
<li>District de Giessen</li>
<li>Hesse (Land)</li>
<li>Svealand</li>
</region>
<settlement><li>Berlin</li>
<li>Marbourg</li>
<li>Stockholm</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
</region>
<name sortKey="Bergtholdt, Bettina" sort="Bergtholdt, Bettina" uniqKey="Bergtholdt B" first="Bettina" last="Bergtholdt">Bettina Bergtholdt</name>
<name sortKey="Koester, Juergen" sort="Koester, Juergen" uniqKey="Koester J" first="Juergen" last="Koester">Juergen Koester</name>
<name sortKey="Reess, Juergen" sort="Reess, Juergen" uniqKey="Reess J" first="Juergen" last="Reess">Juergen Reess</name>
<name sortKey="Schindler, Thomas" sort="Schindler, Thomas" uniqKey="Schindler T" first="Thomas" last="Schindler">Thomas Schindler</name>
<name sortKey="Stiasny Kolster, Karin" sort="Stiasny Kolster, Karin" uniqKey="Stiasny Kolster K" first="Karin" last="Stiasny-Kolster">Karin Stiasny-Kolster</name>
</country>
<country name="Suède"><region name="Svealand"><name sortKey="Hallstrom, Yngve" sort="Hallstrom, Yngve" uniqKey="Hallstrom Y" first="Yngve" last="Hallström">Yngve Hallström</name>
</region>
<name sortKey="Albo, Jaan" sort="Albo, Jaan" uniqKey="Albo J" first="Jaan" last="Albo">Jaan Albo</name>
<name sortKey="Leissner, Lena" sort="Leissner, Lena" uniqKey="Leissner L" first="Lena" last="Leissner">Lena Leissner</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004278 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004278 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:07-0133246 |texte= Efficacy of pramipexole in restless legs syndrome : A six-week, multicenter, randomized, double-blind study (effect-RLS study) }}
This area was generated with Dilib version V0.6.23. |